Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 468Neoplasms 316Carcinoma, Non-Small-Cell Lung 269Prostatic Neoplasms 215Colorectal Neoplasms 208Lung Neoplasms 178Multiple Myeloma 123Melanoma 110Carcinoma, Renal Cell 107Ovarian Neoplasms 94Carcinoma, Hepatocellular 78Pancreatic Neoplasms 69Urinary Bladder Neoplasms 65Stomach Neoplasms 64Neoplasm Metastasis 64Leukemia, Lymphocytic, Chronic, B-Cell 62Colonic Neoplasms 60Leukemia, Myeloid, Acute 53Uterine Cervical Neoplasms 50Recurrence 49Liver Neoplasms 46Lymphoma, Follicular 45Lymphoma 45Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Esophageal Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 35Head and Neck Neoplasms 35Lymphoma, Non-Hodgkin 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Restless Legs Syndrome × Clear all
NCT01138124 2017-05-30

Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)

GlaxoSmithKline

Completed
54,202 enrolled 21 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Diabetes Mellitus, Epilepsy, Hypertension, Kidney Neoplasms, Neuralgia, Pancreatic Neoplasms, Restless Legs Syndrome, Pancreatitis, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡